Below are the most recent publications written about "Tumor Burden" by people in Profiles.
-
Barata PC, Zarrabi KK, Bex A, Grivas P, Hermann K, Hofman MS, Li R, Lopez-Beltran A, Padani AR, Powles T, Taplin ME, Loriot Y. Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers. Eur Urol. 2025 Apr; 87(4):412-423.
-
Bansal R, Sener H, Ganguly A, Shields JA, Shields CL. Metastasis-free survival of uveal melanoma by tumour size category based on The Cancer Genome Atlas (TCGA) classification in 1001 cases. Clin Exp Ophthalmol. 2025 03; 53(2):175-183.
-
Monda SM, Carney BW, May AM, Gulati S, Salami SS, Chandrasekar T, Keller ET, Huebner NA, Palapattu GS, Dall'Era MA. Differences?in mutations across tumour sizes in clear-cell renal cell carcinoma. BJU Int. 2025 Feb; 135(2):269-278.
-
Gulersen M, Krantz D, Rochelson B, Berghella V, Blitz MJ. The association between uterine fibroid number and size and risk of preterm birth. Am J Obstet Gynecol MFM. 2024 08; 6(8):101415.
-
Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, B?gemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR. Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study. Eur Urol. 2024 Oct; 86(4):329-339.
-
Sun G, Eisenbrey JR, Smolock AR, Lallas CD, Anton KF, Adamo RD, Shaw CM. Percutaneous Microwave Ablation versus Cryoablation for Small Renal Masses (=4 cm): 12-Year Experience at a Single Center. J Vasc Interv Radiol. 2024 06; 35(6):865-873.
-
Wilson N, Abdallah M, Schulman AR, Mosko JD, Saeed A, Kothari S, Kaul V, Kothari TH, Phan J, Kumar A, Tofani C, Kim RE, Westanmo A, Moy BM, Dang F, Canakis A, Sharma N, Muniraj T, Azeem N, Bilal M. Outcomes of cold snare EMR of nonampullary duodenal adenomas?=1 cm: a multicenter study. Gastrointest Endosc. 2024 06; 99(6):971-980.e1.
-
Kabir MF, Jackson JL, Fuller AD, Gathuka L, Karami AL, Conde DG, Klochkova A, Mu A, Cai KQ, Klein-Szanto AJ, Muir AB, Whelan KA. Diclofenac exhibits cytotoxic activity associated with metabolic alterations and p53 induction in ESCC cell lines and decreases ESCC tumor burden in vivo. Carcinogenesis. 2023 05 26; 44(2):182-195.
-
Rosenbaum SR, Tiago M, Caksa S, Capparelli C, Purwin TJ, Kumar G, Glasheen M, Pomante D, Kotas D, Chervoneva I, Aplin AE. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects. Cell Rep. 2021 12 07; 37(10):110085.
-
George J, Li Y, Kadamberi IP, Parashar D, Tsaih SW, Gupta P, Geethadevi A, Chen C, Ghosh C, Sun Y, Mittal S, Ramchandran R, Rui H, Lopez-Berestein G, Rodriguez-Aguayo C, Leone G, Rader JS, Sood AK, Dey M, Pradeep S, Chaluvally-Raghavan P. RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. Cell Rep. 2021 11 02; 37(5):109934.